Publication

Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Oliveira, M.
; 
Hamilton, E. P.
; 
Incorvati, J.
; 
de la Heras, B. B.
; 
Calvo, E.
; 
Garcia-Corbacho, J.
; 
Ruiz-Borrego, M.
; 
Vaklavas, C.
; 
Turner, N. C.
; 
Ciruelos, E. M.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Oliveira, M.
Hamilton, E. P.
Incorvati, J.
de la Heras, B. B.
Calvo, E.
Garcia-Corbacho, J.
Ruiz-Borrego, M.
Vaklavas, C.
Turner, N. C.
Ciruelos, E. M.
Patel, M. R.
Armstrong, Anne C
Kabos, P.
Twelves, C.
Brier, T.
Irurzun-Arana, I.
Klinowska, T.
Lindemann, J. P. O.
Morrow, C. J.
Baird, R. D.
Affiliation
Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Oliveira M, Hamilton EP, Incorvati J, de la Heras BB, Calvo E, Garcia-Corbacho J, et al. Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300091.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625793
Embedded videos